Should I buy or sell MiMedx Group stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXG shares. View MDXG analyst ratings or view top-rated stocks .

What is MiMedx Group's stock price target for 2024?

3 brokerages have issued 1 year target prices for MiMedx Group's stock. Their MDXG share price targets range from $11.00 to $12.00. On average, they expect the company's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 46.0% from the stock's current price. View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts .

How have MDXG shares performed in 2023?

MiMedx Group's stock was trading at $2.78 at the beginning of the year. Since then, MDXG shares have increased by 187.4% and is now trading at $7.99. View the best growth stocks for 2023 here .

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our MDXG earnings forecast .

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) posted its quarterly earnings results on Monday, October, 30th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.01. The company earned $81.71 million during the quarter, compared to analyst estimates of $76.69 million.

What ETF holds MiMedx Group's stock ?

Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio.

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannell Capital LLC (1.95%), Richmond Brothers Inc. (1.27%), Charles Schwab Investment Management Inc. (0.92%), Northern Trust Corp (0.92%), Federated Hermes Inc. (0.72%) and Royal Bank of Canada (0.71%). Insiders that own company stock include Mark Graves, Peter M Carlson, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan. View institutional ownership trends .

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

MiMedx Group Stock Price, News & Analysis (NASDAQ:MDXG)

$7.99

+0.22 (+2.83%)

(As of 12/1/2023 ET)

Compare

Today's Range: $7.61
▼
$7.99
50-Day Range: $5.70
▼
$7.99
52-Week Range: $2.43
▼
$8.60

Volume: 626,117 shs
Average Volume: 651,481 shs
Market Capitalization: $929.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.67

MiMedx Group MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 46.0% Upside
$11.67 Price Target
Short Interest: Healthy
3.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$35,800 Bought Last Quarter
Proj. Earnings Growth: 277.78%
From $0.09 to $0.34 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

101st out of 954 stocks

Surgical & Medical Instruments Industry

17th out of 95 stocks

3.5

Analyst's Opinion

Consensus Rating
MiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.67, MiMedx Group has a forecasted upside of 46.0% from its current price of $7.99.
Amount of Analyst Coverage
MiMedx Group has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.72% of the float of MiMedx Group has been sold short.
Short Interest Ratio / Days to Cover
MiMedx Group has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in MiMedx Group has recently decreased by 12.18%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MiMedx Group does not currently pay a dividend.
Dividend Growth
MiMedx Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDXG.

2.2

News and Social Media Coverage

News Sentiment
MiMedx Group has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for MiMedx Group this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for MDXG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MiMedx Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,800.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
19.90% of the stock of MiMedx Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.85% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for MiMedx Group are expected to grow by 277.78% in the coming year, from $0.09 to $0.34 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MiMedx Group is -399.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MiMedx Group is -399.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MiMedx Group has a P/B Ratio of 799.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MiMedx Group Stock (NASDAQ:MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MDXG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDXG Stock News Headlines

November 25, 2023 | morningstar.com

MiMedx Group Inc MDXG

November 13, 2023 | finance.yahoo.com

MIMEDX to Participate in Upcoming Investor Conferences

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 2, 2023 | finance.yahoo.com

MIMEDX to Highlight Published Data at SAWC Fall

November 2, 2023 | finance.yahoo.com

Loss-Making MiMedx Group, Inc. (NASDAQ:MDXG) Set To Breakeven

November 1, 2023 | msn.com

Mizuho Maintains Mimedx Group (MDXG) Buy Recommendation

November 1, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG) and Repligen (RGEN)

October 31, 2023 | msn.com

MDXG: Xenografts and Synthetics Options for Expansion

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 31, 2023 | finance.yahoo.com

MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2023 Earnings Call Transcript

October 31, 2023 | finance.yahoo.com

Q3 2023 MiMedx Group Inc Earnings Call

October 31, 2023 | finanznachrichten.de

MiMedx Group, Inc: MIMEDX Announces Third Quarter 2023 Operating and Financial Results

October 30, 2023 | msn.com

MiMedx Group Non-GAAP EPS of $0.05 in-line, revenue of $81.71M beats by $3.77M

October 30, 2023 | finance.yahoo.com

MiMedx Group Inc (MDXG) Reports 20.7% Increase in Q3 2023 Net Sales

October 28, 2023 | msn.com

Craig-Hallum Initiates Coverage of Mimedx Group (MDXG) with Buy Recommendation

October 27, 2023 | msn.com

MiMedx Group Q3 Earnings Preview

October 16, 2023 | finance.yahoo.com

MIMEDX to Host Third Quarter 2023 Operating and Financial Results Conference Call on October 30

October 6, 2023 | finance.yahoo.com

Investing in MiMedx Group (NASDAQ:MDXG) a year ago would have delivered you a 161% gain

October 4, 2023 | seekingalpha.com

Unraveling MiMedx's Surgical Precision In Growth

September 26, 2023 | finance.yahoo.com

MIMEDX Announces Launch of EPIEFFECT™

August 31, 2023 | msn.com

Mimedx Group (MDXG) Price Target Increased by 19.14% to 12.30

August 15, 2023 | finance.yahoo.com

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

August 10, 2023 | seekingalpha.com

MiMedx Group, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 2, 2023 | finance.yahoo.com

MDXG: Beat and a Raise

August 2, 2023 | finance.yahoo.com

Q2 2023 MiMedx Group Inc Earnings Call

August 2, 2023 | finanznachrichten.de

MiMedx Group, Inc: MIMEDX Announces Second Quarter 2023 Operating and Financial Results

August 2, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for MiMedx Group (MDXG)

See More Headlines

Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/30/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MDXG
CUSIP: N/A
CIK: 1376339
Web: www.mimedx.com
Phone: (770) 651-9100
Fax: 678-384-6741
Employees: 867
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.67
High Stock Price Target: $12.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +46.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 88.78
P/E Growth: N/A
Net Income: $-30,200,000.00
Net Margins: -0.82%
Pretax Margin: 1.60%
Return on Equity: N/A
Return on Assets: -0.72%

Debt

Debt-to-Equity Ratio: 36.82
Current Ratio: 3.54
Quick Ratio: 3.10

Sales & Book Value

Annual Sales: $267.84 million
Price / Sales: 3.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.01 per share
Price / Book: 799.00

Miscellaneous

Outstanding Shares: 116,380,000
Free Float: 93,218,000
Market Cap: $929.88 million
Optionable: Optionable
Beta: 1.63

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. William F. Hulse IV (Age 49)
General Counsel & Chief Administrative Officer
Comp: $677.36k
Dr. Robert Benjamin Stein M.D. (Age 72)
Ph.D., President of Regenerative Medicine & Biologics Innovation
Comp: $639.28k
Mr. Joseph H. Capper (Age 59)
CEO & Director
Mr. Douglas C. Rice CPA (Age 57)
Chief Financial Officer
Mr. Scott M. Turner (Age 57)
Senior Vice President of Operations & Procurement
Comp: $493.98k
Mr. Matthew M. Notarianni
Head of Investor Relations
Mr. Mark P. Graves (Age 57)
Senior VP & Chief Compliance Officer
Hilary Dixon
Vice President of Investor Relations & Corporate Strategic Communications
Ms. Kate Surdez
Chief Human Resources Officer
Dr. David H. Mason Jr. (Age 76)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDXG Stock Analysis - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings or view top-rated stocks.
What is MiMedx Group's stock price target for 2024?: 3 brokerages have issued 1 year target prices for MiMedx Group's stock. Their MDXG share price targets range from $11.00 to $12.00. On average, they expect the company's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 46.0% from the stock's current price.
View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts.
How have MDXG shares performed in 2023?: MiMedx Group's stock was trading at $2.78 at the beginning of the year. Since then, MDXG shares have increased by 187.4% and is now trading at $7.99.
View the best growth stocks for 2023 here.
When is MiMedx Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our MDXG earnings forecast.

How were MiMedx Group's earnings last quarter?: MiMedx Group, Inc. (NASDAQ:MDXG) posted its quarterly earnings results on Monday, October, 30th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.01. The company earned $81.71 million during the quarter, compared to analyst estimates of $76.69 million.
What ETF holds MiMedx Group's stock ?: Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio.
Who are MiMedx Group's major shareholders?: MiMedx Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannell Capital LLC (1.95%), Richmond Brothers Inc. (1.27%), Charles Schwab Investment Management Inc. (0.92%), Northern Trust Corp (0.92%), Federated Hermes Inc. (0.72%) and Royal Bank of Canada (0.71%). Insiders that own company stock include Mark Graves, Peter M Carlson, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends.
How do I buy shares of MiMedx Group?: Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MDXG) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial